Joinn Laboratories (China) (HKG:6127, SHA:603127) expects a net profit attributable to shareholders of around 58.7 million yuan and 88.0 million yuan for 2024, representing a between 77.8% to 85.2% year-over-year decline.
The drug developer attributed the forecast to lower gross profit margins and the decrease in the market price of biological assets held by the company, a Friday Hong Kong bourse filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。